|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of tumor metastasis suppressor gene KAI1 in digestive tract carcinomas and cancer cells.
|
12955496 |
2003 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, most of the primary HCC cells in samples with metastases showed only faint or moderate KAI1 mRNA expression predominantly in the perinuclear regions.
|
9828210 |
1998 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 is a metastasis suppressor gene which is capable of inhibiting the processes of tumor metastasis without affecting tumorigenicity per se.
|
10913345 |
2000 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased level of KAI1/CD82 also results in the suppression of secondary tumour growth.
|
19224455 |
2009 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Kangai 1 (KAI1) is considered as a suppressor gene of tumor metastasis.
|
31725636 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Vasculogenic mimicry (VM, new blood supply formation in malignant tumors), E-Cadherin (a calcium-dependent transmembrane glycoprotein that mediates intercellular adhesion), KAI1 (a suppressor gene of tumor metastasis) are all valuable factors for metastasis and prognosis in diverse common human cancers.
|
30290593 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study suggests an association of decreased KAI1/CD82 expression with tumour progression, development of metastases and disease-specific death.
|
18305955 |
2008 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1/CD82 has been reported to attenuate the process of metastases in a variety of tumors; however, its mechanism of action in invasion has not been fully elucidated.
|
21459729 |
2011 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The tetraspanin CD82 is a potent suppressor of tumor metastasis and regulates several processes including signal transduction, cell adhesion, motility, and aggregation.
|
31408613 |
2019 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, KAI1 mRNA expression was similar in primary esophageal and gastric cancer samples with or without metastases.
|
9485031 |
1998 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this review, we focus on the differential expression of KAI1/CD82, a tumor metastasis suppressor gene that can inhibit cancer invasion and cell metastasis during NSCLC.
|
29283339 |
2017 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downregulation of KAI1 has been found to be clinically associated with metastatic progression in a variety of cancers, whereas overexpression of CD82 specifically suppresses tumor metastasis in various animal models.
|
16862154 |
2006 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, tumor suppressor genes such as KAI1 are expressed at reduced levels, thereby enhancing the ability of pancreatic cells to form metastases.
|
12120231 |
2001 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
SIGNIFICANCE STATEMENT: The cell-surface and ER transmembrane protein gp78/AMFR, a receptor for the prometastatic autocrine motility factor (AMF), as well as an E3 ubiquitin-ligase involved in the ER-associated degradation (ERAD) of not only the tumor metastatic suppressor KAI1 but also of hepatic cytochromes P450, is upregulated in various human cancers, enhancing their invasiveness, metastatic potential, and poor prognosis.
|
31492698 |
2019 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subsequent investigations revealed that Cx32 directly enhanced the acetylation and transcriptional activity of p53, thus upregulating the expression of the tumor metastasis suppressor protein KAI1/CD82, which is a p53 target gene.
|
25426556 |
2015 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of CD82 and CD63 was analysed by reverse transcriptase-PCR (RT-PCR) and immunohistochemistry in benign goiter (n=12) and 75 primary thyroid carcinoma tissue specimens (PTC: 33, FTC: 24, UTC: 18) out of which 36 were non-metastasized primary tumors and 39 were metastasized tumors (regional lymph node and/or distant metastases).
|
15375577 |
2004 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
KAI1 is a tumor metastasis suppressor gene that is capable of inhibiting the metastatic process in animals.
|
9736732 |
1998 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The KAI1/CD82 protein has been documented as the tumor metastasis suppressor in many types of human cancers.
|
17560548 |
2007 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Statistical analysis of KAI1 mRNA levels and clinical parameters of the patients revealed that KAI1 mRNA levels were significantly higher in non-metastasized tumors compared with tumors in which lymph node or distant metastases were present.
|
9699525 |
1998 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In RA-synovium, CD82 was expressed in RASF close to blood vessels, LL, sites of cartilage invasion and colocalised with distinct integrins involved in tumour metastasis suppression but also in RA-synovium by RASF.
|
29980577 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased KAI1 expression significantly correlated with distant metastases (Mann-Whitney, p = 0.0001, mRNA; p = 0.033, protein), cancer-specific survival (Cox regression analysis p = 0.0002, mRNA; 0.0493, protein) and overall patient survival (p = 0.0001, mRNA).
|
12530084 |
2003 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Induction of KAI-1 expression in metastatic cancer cells by phorbol esters.
|
10779634 |
2000 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data demonstrate that the KAI1 mRNA expression and the KAI1 protein level increase in an earlier tumor stage of colorectal cancer, decrease in advanced stages, and are lost in metastases.
|
10568187 |
1999 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In multivariate analysis, high VM, Notch4, DLL4 levels, tumor size, LNM, DM, TNM stage, and low KAI1/CD82 levels were potential to be independent prognostic factors for overall survival time (OST) in NSCLC patients.VM and the expression of Notch4, DLL4, and KAI1/CD82 represent promising markers for tumor metastasis and prognosis, and maybe potential therapeutic targets for NSCLC.
|
30593175 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The tetraspanin KAI1/CD82 was identified as a tumor metastasis suppressor that downregulated in various malignant cell types.
|
28881668 |
2017 |